After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential

Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.